GO
Loading...

Enter multiple symbols separated by commas

Stocks Gilead Sciences Inc

More

  • NEW YORK— The U.S. stock market endured its worst performance in 18 months on Thursday, driven lower by another slump in Chinese shares and heavy selling by technical traders. The global rout started in China, where sharp declines in energy and property stocks pushed the Shanghai Composite down more than 3 percent. "The emerging markets really got slammed...

  • Apple alone counts for a huge part of Nasdaq risk Thursday, 6 Aug 2015 | 11:04 AM ET
    Shoppers look at iPhones at an Apple store in New York

    Data from Axioma show that the most concentrated risk in the Nasdaq 100 is confined to the top six stocks.

  • The most loved stocks on Wall Street Friday, 31 Jul 2015 | 9:41 AM ET
    Traders on the floor of the New York Stock Exchange.

    Despite muted returns for the S&P 500 in 2015, analysts on Wall Street just love these stocks.

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher after the Fed kept rates unchanged and the continued recovery in oil prices encouraged investor sentiment.

  • *Fed statement expected at 2 p.m. ET. *Yelp falls sharply after revenue misses expectations. The statement is expected at 2 p.m. ET.

  • Early movers: HLT, ANTM, ETN, TWTR, GSK & more Wednesday, 29 Jul 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-U.S. futures higher ahead of Fed statement Wednesday, 29 Jul 2015 | 7:28 AM ET

    July 29- U.S. stock index futures rose on Wednesday on hopes that Beijing could stem the rout in its markets and ahead of a statement from the U.S. *In a recent congressional testimony, Fed Chair Janet Yellen neither ruled out a September interest rate hike nor guided the market toward thinking it was a done deal. The statement is expected at 2 p.m. ET.

  • July 28- Gilead Sciences Inc said on Tuesday sales of its hepatitis C drugs hit a record of nearly $5 billion, surpassing Wall Street estimates as strong demand offset pricing pressures and restrictions on patient use from U.S. health insurers. Excluding items, Gilead earned $3.15 a share in the second quarter, beating the $2.71 average forecast by Wall Street...

  • Your first trade for Wednesday Tuesday, 28 Jul 2015 | 6:26 PM ET

    The "Fast Money" traders awarded their final grades to the Gilead, Twitter and Yelp following their quarterly earnings reports.

  • After-hours buzz: Yelp, Akamai, Panera & more Tuesday, 28 Jul 2015 | 5:52 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Tuesday: Yelp, Akamai, Panera & more.

  • Gilead posts huge beat on earnings and revenue Tuesday, 28 Jul 2015 | 5:28 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.

  • July 28- Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. Excluding items, Gilead earned $3.15 a share in the second quarter, exceeding the...

  • *Focus on corporate results eclipses China worry. *Twitter and Gilead up after the bell; Yelp drops. "The S&P has had five down days in a row and a lot of people are starting to nibble," said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1 billion.

  • Top trades to go: Earnings edition Tuesday, 28 Jul 2015 | 1:43 PM ET

    The "Halftime Report" traders give their trades on earnings for the second half.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • Cramer game plan—My Fed-pectations in week ahead Friday, 24 Jul 2015 | 6:13 PM ET
    Federal Reserve Board Chair Janet Yellen testifies before a House Financial Services committee hearing on Capitol Hill in Washington, July 15, 2015.

    Jim Cramer lays out his game plan next week. It will all about the Fed, Fed, Fed with a side of China.

  • Battle coming for blockbuster cholesterol drugs Friday, 24 Jul 2015 | 3:59 PM ET
    A Sanofi lab worker packages vaccines.

    One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • *AbbVie CEO sees 2015 Humira growth in mid-teens. July 24 (Reuters)- AbbVie Inc reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sparking concerns over slowing sales growth for its flagship arthritis drug, Humira. AbbVie reported total Humira sales of $3.54 billion for the quarter ended June 30, a 7.6 percent fall from a...